Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Treats migraine with or without aura. Sold as Maxalt, Maxalt-Mlt, Rizafilm. Every FDA application for this active ingredient: 3 branded and 25 generic.
As of Nov 14, 2026, FDA lists 28 applications for Rizatriptan Benzoate (sold as Maxalt, Maxalt-Mlt, Rizafilm), first approved Jun 29, 1998, with 9 new uses approved and 3 published complete response letters.
First approved: Jun 29, 1998
Applications: 28
New uses approved: 9
Complete response letters: 3
Medicare spending, 2025: $19.9M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Rizatriptan
Part D
$17.7M
+22%
214,163
Maxalt
Part D
$1.1M
-1%
282
Maxalt Mlt
Part D
$1.1M
-3%
360
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
MAXALT 10 MG TABLET: $44.25 per unitBrand · +4% in a year
MAXALT MLT 10 MG TABLET: $44.23 per unitBrand · +5% in a year
Clinical Trials
1 open or ongoing study names this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Organon
Sandoz